Therapy Detail

Therapy Name DZNep + MK2206
Therapy Description

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
DZNeP 3-Deazaneplanocin A EZH2 inhibitor 16 DZNeP (3-Deazaneplanocin A) inhibits S-adenosylhomocysteine hydrolase, resulting in depletion of EZH2 and inhibition of H3K27 methylation, which may promote apoptosis in cancer cells (PMID: 3790170, PMID: 19638619).
MK2206 MK-2206 Akt Inhibitor (Pan) 17 MK2206 binds to and inhibits the activity of AKT in a non-ATP competitive manner, which may result in the inhibition of the PI3K/AKT signaling pathway and tumor cell proliferation (PMID: 20571069).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
KRAS G12C EZH2 pos lung adenocarcinoma no benefit DZNep + MK2206 Preclinical - Cell culture Actionable In a preclinical study, the addition of DZNep did not increase sensitivity to MK2206 in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12C (PMID: 26676756). 26676756
KRAS G12D EZH2 pos lung adenocarcinoma sensitive DZNep + MK2206 Preclinical - Cell line xenograft Actionable In a preclinical study, the addition of DZNep increased sensitivity to MK2206 in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12D in culture and in xenograft models, resulting in decreased cell survival and tumor growth (PMID: 26676756). 26676756
KRAS G12D EZH2 pos colon cancer sensitive DZNep + MK2206 Preclinical - Cell culture Actionable In a preclinical study, the addition of DZNep increased sensitivity to MK2206 in an EZH2-expressing colon cancer cell line harboring KRAS G12D in culture (PMID: 26676756). 26676756
KRAS G12S EZH2 pos lung adenocarcinoma sensitive DZNep + MK2206 Preclinical - Cell culture Actionable In a preclinical study, the addition of DZNep increased sensitivity to MK2206 in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12S in culture (PMID: 26676756) 26676756
KRAS G12D EZH2 pos pancreatic cancer sensitive DZNep + MK2206 Preclinical - Cell culture Actionable In a preclinical study, the addition of DZNep increased sensitivity to MK2206 in an EZH2-expressing pancreatic cancer cell line harboring KRAS G12D in culture (PMID: 26676756). 26676756
KRAS G12C EZH2 pos pancreatic cancer sensitive DZNep + MK2206 Preclinical - Cell culture Actionable In a preclinical study, the addition of DZNep increased sensitivity to MK2206 in an EZH2-expressing pancreatic cancer cell line harboring KRAS G12C in culture (PMID: 26676756). 26676756
KRAS G12V EZH2 pos lung adenocarcinoma no benefit DZNep + MK2206 Preclinical - Cell culture Actionable In a preclinical study, the addition of DZNep did not increase sensitivity to MK2206 in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12V (PMID: 26676756). 26676756
Clinical Trial Phase Therapies Title Recruitment Status